Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children: a Multicentre European Randomized Controlled Trial

Next Previous
Trial Profile

Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children: a Multicentre European Randomized Controlled Trial

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Immune globulin (Primary) ; Albumin human
  • Indications Septic shock; Staphylococcal infections; Streptococcal infections
  • Focus Therapeutic Use
  • Acronyms IGHN2

    • Most Recent Events

    • 26 Feb 2018 Planned End Date changed from 1 Jan 2021 to 1 Apr 2022.
    • 26 Feb 2018 Planned primary completion date changed from 1 Jan 2021 to 1 Apr 2022.
    • 26 Feb 2018 Planned initiation date changed from 1 Jan 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top